Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 257

1.

Author Correction: Probiotics and prebiotics in intestinal health and disease: from biology to the clinic.

Sanders ME, Merenstein DJ, Reid G, Gibson GR, Rastall RA.

Nat Rev Gastroenterol Hepatol. 2019 Aug 9. doi: 10.1038/s41575-019-0199-6. [Epub ahead of print]

PMID:
31399728
2.

Correction to: Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data.

Finotello F, Mayer C, Plattner C, Laschober G, Rieder D, Hackl H, Krogsdam A, Loncova Z, Posch W, Wilflingseder D, Sopper S, Ijsselsteijn M, Brouwer TP, Johnson D, Xu Y, Wang Y, Sanders ME, Estrada MV, Ericsson-Gonzalez P, Charoentong P, Balko J, da Cunha Carvalho de Miranda NF, Trajanoski Z.

Genome Med. 2019 Jul 29;11(1):50. doi: 10.1186/s13073-019-0655-5.

3.

A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis.

Johnson DB, McDonnell WJ, Gonzalez-Ericsson PI, Al-Rohil RN, Mobley BC, Salem JE, Wang DY, Sanchez V, Wang Y, Chastain CA, Barker K, Liang Y, Warren S, Beechem JM, Menzies AM, Tio M, Long GV, Cohen JV, Guidon AC, O'Hare M, Chandra S, Chowdhary A, Lebrun-Vignes B, Goldinger SM, Rushing EJ, Buchbinder EI, Mallal SA, Shi C, Xu Y, Moslehi JJ, Sanders ME, Sosman JA, Balko JM.

Nat Med. 2019 Aug;25(8):1243-1250. doi: 10.1038/s41591-019-0523-2. Epub 2019 Jul 22.

PMID:
31332390
4.

Probiotics and prebiotics in intestinal health and disease: from biology to the clinic.

Sanders ME, Merenstein DJ, Reid G, Gibson GR, Rastall RA.

Nat Rev Gastroenterol Hepatol. 2019 Jul 11. doi: 10.1038/s41575-019-0173-3. [Epub ahead of print] Review. Erratum in: Nat Rev Gastroenterol Hepatol. 2019 Aug 9;:.

PMID:
31296969
5.

p73 regulates epidermal wound healing and induced keratinocyte programming.

Beeler JS, Marshall CB, Gonzalez-Ericsson PI, Shaver TM, Santos Guasch GL, Lea ST, Johnson KN, Jin H, Venters BJ, Sanders ME, Pietenpol JA.

PLoS One. 2019 Jun 19;14(6):e0218458. doi: 10.1371/journal.pone.0218458. eCollection 2019.

6.

Identification of Targetable Recurrent MAP3K8 Rearrangements in Melanomas Lacking Known Driver Mutations.

Lehmann BD, Shaver TM, Johnson DB, Li Z, Gonzalez-Ericsson PI, Sánchez V, Shyr Y, Sanders ME, Pietenpol JA.

Mol Cancer Res. 2019 Jun 11. doi: 10.1158/1541-7786.MCR-19-0257. [Epub ahead of print]

PMID:
31186280
7.

More Information Needed on Probiotic Supplement Product Labels.

Merenstein D, Guzzi J, Sanders ME.

J Gen Intern Med. 2019 Jun 3. doi: 10.1007/s11606-019-05077-5. [Epub ahead of print] No abstract available.

PMID:
31161565
8.

Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data.

Finotello F, Mayer C, Plattner C, Laschober G, Rieder D, Hackl H, Krogsdam A, Loncova Z, Posch W, Wilflingseder D, Sopper S, Ijsselsteijn M, Brouwer TP, Johnson D, Xu Y, Wang Y, Sanders ME, Estrada MV, Ericsson-Gonzalez P, Charoentong P, Balko J, de Miranda NFDCC, Trajanoski Z.

Genome Med. 2019 May 24;11(1):34. doi: 10.1186/s13073-019-0638-6. Erratum in: Genome Med. 2019 Jul 29;11(1):50.

9.

Improving End-User Trust in the Quality of Commercial Probiotic Products.

Jackson SA, Schoeni JL, Vegge C, Pane M, Stahl B, Bradley M, Goldman VS, Burguière P, Atwater JB, Sanders ME.

Front Microbiol. 2019 Apr 17;10:739. doi: 10.3389/fmicb.2019.00739. eCollection 2019. Review.

10.

Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities.

Vasaikar S, Huang C, Wang X, Petyuk VA, Savage SR, Wen B, Dou Y, Zhang Y, Shi Z, Arshad OA, Gritsenko MA, Zimmerman LJ, McDermott JE, Clauss TR, Moore RJ, Zhao R, Monroe ME, Wang YT, Chambers MC, Slebos RJC, Lau KS, Mo Q, Ding L, Ellis M, Thiagarajan M, Kinsinger CR, Rodriguez H, Smith RD, Rodland KD, Liebler DC, Liu T, Zhang B; Clinical Proteomic Tumor Analysis Consortium.

Cell. 2019 May 2;177(4):1035-1049.e19. doi: 10.1016/j.cell.2019.03.030. Epub 2019 Apr 25.

11.

Author Correction: Drug response in organoids generated from frozen primary tumor tissues.

Walsh AJ, Cook RS, Sanders ME, Arteaga CL, Skala MC.

Sci Rep. 2019 Apr 24;9(1):6517. doi: 10.1038/s41598-019-42133-w.

12.

Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.

Formisano L, Lu Y, Servetto A, Hanker AB, Jansen VM, Bauer JA, Sudhan DR, Guerrero-Zotano AL, Croessmann S, Guo Y, Ericsson PG, Lee KM, Nixon MJ, Schwarz LJ, Sanders ME, Dugger TC, Cruz MR, Behdad A, Cristofanilli M, Bardia A, O'Shaughnessy J, Nagy RJ, Lanman RB, Solovieff N, He W, Miller M, Su F, Shyr Y, Mayer IA, Balko JM, Arteaga CL.

Nat Commun. 2019 Mar 26;10(1):1373. doi: 10.1038/s41467-019-09068-2.

13.

Effects of land vs water jump exercise: Implications for exercise design targeting bone health.

Chien KY, Chang WG, Sanders ME, Chen CH, Wu WC, Chen WC.

Scand J Med Sci Sports. 2019 Jun;29(6):826-834. doi: 10.1111/sms.13410. Epub 2019 Mar 29.

PMID:
30779462
14.

Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.

Loi S, Dushyanthen S, Beavis PA, Salgado R, Denkert C, Savas P, Combs S, Rimm DL, Giltnane JM, Estrada MV, Sánchez V, Sanders ME, Cook RS, Pilkinton MA, Mallal SA, Wang K, Miller VA, Stephens PJ, Yelensky R, Doimi FD, Gómez H, Ryzhov SV, Darcy PK, Arteaga CL, Balko JM.

Clin Cancer Res. 2019 Feb 15;25(4):1437. doi: 10.1158/1078-0432.CCR-18-4264. No abstract available.

PMID:
30770496
15.

Correction: Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer.

Jansen VM, Bhola NE, Bauer JA, Formisano L, Lee KM, Hutchinson KE, Witkiewicz AK, Moore PD, Estrada MV, Sánchez V, Ericsson PG, Sanders ME, Pohlmann PR, Pishvaian MJ, Riddle DA, Dugger TC, Wei W, Knudsen ES, Arteaga CL.

Cancer Res. 2019 Feb 15;79(4):874. doi: 10.1158/0008-5472.CAN-18-4086. No abstract available.

PMID:
30770369
16.

Correction: Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer.

Hanker AB, Estrada MV, Bianchini G, Moore PD, Zhao J, Cheng F, Koch JP, Gianni L, Tyson DR, Sánchez V, Rexer BN, Sanders ME, Zhao Z, Stricker TP, Arteaga CL.

Cancer Res. 2019 Feb 15;79(4):873. doi: 10.1158/0008-5472.CAN-18-4085. No abstract available.

PMID:
30770368
17.

Enhancing Parathyroid Gland Visualization Using a Near Infrared Fluorescence-Based Overlay Imaging System.

McWade MA, Thomas G, Nguyen JQ, Sanders ME, Solórzano CC, Mahadevan-Jansen A.

J Am Coll Surg. 2019 May;228(5):730-743. doi: 10.1016/j.jamcollsurg.2019.01.017. Epub 2019 Feb 13.

PMID:
30769112
18.

Probiotic Safety-Reasonable Certainty of No Harm.

Cabana MD, Salminen S, Sanders ME.

JAMA Intern Med. 2019 Feb 1;179(2):276. doi: 10.1001/jamainternmed.2018.7498. No abstract available.

PMID:
30715110
19.

Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement.

Johnson DB, Nixon MJ, Wang Y, Wang DY, Castellanos E, Estrada MV, Ericsson-Gonzalez PI, Cote CH, Salgado R, Sanchez V, Dean PT, Opalenik SR, Schreeder DM, Rimm DL, Kim JY, Bordeaux J, Loi S, Horn L, Sanders ME, Ferrell PB Jr, Xu Y, Sosman JA, Davis RS, Balko JM.

JCI Insight. 2018 Dec 20;3(24). pii: 120360. doi: 10.1172/jci.insight.120360.

20.

Innovative surgical guidance for label-free real-time parathyroid identification.

Thomas G, McWade MA, Nguyen JQ, Sanders ME, Broome JT, Baregamian N, Solórzano CC, Mahadevan-Jansen A.

Surgery. 2019 Jan;165(1):114-123. doi: 10.1016/j.surg.2018.04.079. Epub 2018 Nov 12.

PMID:
30442424

Supplemental Content

Loading ...
Support Center